by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
by Truveta staff | Oct 10, 2024 | Data
The US market size for joint replacement is projected to balloon to nearly $38 billion by 2030, nearly doubling its 2022 value. The combination of an aging population, increasing rates of osteoarthritis and obesity, along with advancing technology, are all...
by Truveta staff | Sep 13, 2024 | Data
Mother and child health are inherently interconnected, offering unique insights into how maternal health, behaviors, and exposures impact child outcomes. Unfortunately, the potential of this data has historically been limited by challenges in data collection, the long...
by Truveta staff | Aug 15, 2024 | Data
Psoriasis is more than just a skin condition – it’s a chronic, systemic disease that affects over 8 million people in the United States, profoundly impacting their quality of life. As a complex, immune-mediated disease, psoriasis presents a variety of challenges to...
by Truveta staff | Jul 30, 2024 | Data
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the 5-year survival rate for patients with ovarian cancer remains less than 30%. Sometimes...
